

## MODULE 2.6.5. PHARMACOKINETICS TABULATED SUMMARY

This document contains confidential information belonging to BioNTech/Pfizer. Except as may be otherwise agreed to in writing, by accepting or reviewing these materials, you agree to hold such information in confidence and not to disclose it to others (except where required by applicable law), nor to use it for unauthorized purposes. In the event of actual or suspected breach of this obligation, BioNTech/Pfizer should be promptly notified.

**2.6.5.1. PHARMACOKINETICS OVERVIEW**

**Test Article: BNT162b2**

Type of Study	Test System	Test item	Method of Administration	Testing Facility	Report Number
<b>Single Dose Pharmacokinetics</b>					
Single Dose Pharmacokinetics and Excretion in Urine and Feces of ALC-0159 and ALC-0315	Rat (Wistar Han)	modRNA encoding luciferase formulated in LNP comparable to BNT162b2	IV bolus	Pfizer Inc <sup>a</sup>	PF-07302048_06Jul20_072424
<b>Distribution</b>					
In Vivo Distribution	Mice BALB/c	modRNA encoding luciferase formulated in LNP comparable to BNT162b2	IM Injection	BioNTech <sup>b</sup>	R-20-0072
<b>Metabolism</b>					
<b>In Vitro and In Vivo Metabolism</b>					
In Vitro Metabolic Stability of ALC-0315 in Liver Microsomes	Mouse (CD-1/ICR), rat (Sprague Dawley and Wistar Han), monkey (Cynomolgus), and human liver microsomes	ALC-0315	In vitro	Medicilon Preclinical Research LLC <sup>c</sup>	01049-20008
In Vitro Metabolic Stability of ALC-0315 in Liver S9	Mouse (CD-1/ICR), rat (Sprague Dawley), monkey (Cynomolgus), and human S9 liver fractions	ALC-0315	In vitro	Medicilon Preclinical Research LLC <sup>c</sup>	01049-20009
In Vitro Metabolic Stability of ALC-0315 in Hepatocytes	Mouse (CD-1/ICR), rat (Sprague Dawley and Wistar Han), monkey (Cynomolgus), and human hepatocytes	ALC-0315	In vitro	Medicilon Preclinical Research LLC <sup>c</sup>	01049-20010

**2.6.5.1. PHARMACOKINETICS OVERVIEW**

**Test Article: BNT162b2**

Type of Study	Test System	Test item	Method of Administration	Testing Facility	Report Number
In Vitro Metabolic Stability of ALC-0159 in Liver Microsomes	Mouse (CD-1/ICR), rat (Sprague Dawley and Wistar Han), monkey (Cynomolgus), and human liver microsomes	ALC-0159	In vitro	Medicilon Preclinical Research LLC <sup>c</sup>	01049-20020
In Vitro Metabolic Stability of ALC-0159 in Liver S9	Mouse (CD-1/ICR), rat (Sprague Dawley), monkey (Cynomolgus), and human S9 fractions	ALC-0159	In vitro	Medicilon Preclinical Research LLC <sup>c</sup>	01049-20021
In Vitro Metabolic Stability of ALC-0159 in Hepatocytes	Mouse (CD-1/ICR), rat (Sprague Dawley and Wistar Han), monkey (Cynomolgus), and human hepatocytes	ALC-0159	In vitro	Medicilon Preclinical Research LLC <sup>c</sup>	01049-20022
Biotransformation of ALC-0159 and ALC-0315 In Vitro and In Vivo in Rats	In vitro: CD-1 mouse, Wistar Han rat, cynomolgus monkey, and human blood, liver S9 fractions and hepatocytes In vivo: male Wistar Han rats	ALC-0315 and ALC-0159	In vitro or IV (in vivo in rats)	Pfizer Inc <sup>d</sup>	PF-07302048_05Aug20_043725

ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide), a proprietary polyethylene glycol-lipid included as an excipient in the LNP formulation used in BNT162b2; ALC-0315 = (4-hydroxybutyl)azanediylbis(hexane-6,1-diyl)bis(2-hexyldecanoate), a proprietary aminolipid included as an excipient in the LNP formulation used in BNT162b2; IM = Intramuscular; IV = Intravenous; LNP = lipid nanoparticles; S9 = Supernatant fraction obtained from liver homogenate by centrifuging at 9000 g.

- a. La Jolla, California.
- b. Mainz, Germany.
- c. Shanghai, China.
- d. Groton, Connecticut.

090177e1950bbf6fApprovedApproved On: 29-Sep-2020 20:17 (GMT)

**2.6.5.3. PHARMACOKINETICS:  
PHARMACOKINETICS AFTER A SINGLE DOSE**

**Test Article: modRNA encoding luciferase in LNP  
Report Number: PF-07302048\_06Jul20\_072424**

Species (Strain)	Rat (Wistar Han)	
Sex/Number of Animals	Male/ 3 animals per timepoint <sup>a</sup>	
Feeding Condition	Fasted	
Method of Administration	IV	
Dose modRNA (mg/kg)	1	
Dose ALC-0159 (mg/kg)	1.96	
Dose ALC-0315 (mg/kg)	15.3	
Sample Matrix	Plasma	
Sampling Time Points (h post dose):	Predose, 0.1, 0.25, 0.5, 1, 3, 6, 24, 48, 96, 192, 336	
Analyte	ALC-0315	ALC-0159
PK Parameters:	Mean <sup>b</sup>	Mean <sup>b</sup>
AUC <sub>inf</sub> (µg•h/mL) <sup>c</sup>	1030	99.2
AUC <sub>last</sub> (µg•h/mL)	1020	98.6
Initial t <sub>½</sub> (h) <sup>d</sup>	1.62	1.74
Terminal elimination t <sub>½</sub> (h) <sup>e</sup>	139	72.7
Estimated fraction of dose distributed to liver (%) <sup>f</sup>	59.5	20.3
Dose in Urine (%)	NC <sup>g</sup>	NC <sup>g</sup>
Dose in Feces (%) <sup>h</sup>	1.05	47.2

ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide), a proprietary polyethylene glycol-lipid included as an excipient in the LNP formulation used in BNT162b2; ALC-0315 = (4-hydroxybutyl)azanediylbis(hexane-6,1-diy)bis(2-hexyldecanoate), a proprietary aminolipid included as an excipient in the LNP formulation used in BNT162b2; AUC<sub>inf</sub> = Area under the plasma drug concentration-time curve from 0 to infinite time; AUC<sub>last</sub> = Area under the plasma drug concentration-time curve from 0 to the last quantifiable time point; BLQ = Below the limit of quantitation; LNP = Lipid nanoparticle; modRNA = Nucleoside modified messenger RNA; PK = Pharmacokinetics; t<sub>½</sub> = Half-life.

- Non-serial sampling, 36 animals total.
- Only mean PK parameters are reported due to non-serial sampling.
- Calculated using the terminal log-linear phase (determined using 48, 96, 192, and 336 h for regression calculation).
- ln(2)/initial elimination rate constant (determined using 1, 3, and 6 h for regression calculation).
- ln(2)/terminal elimination rate constant (determined using 48, 96, 192, and 336 h for regression calculation).
- Calculated as follows: highest mean amount in the liver (µg)/total mean dose (µg) of ALC-0315 or ALC-0159.
- Not calculated due to BLQ data.
- Fecal excretion, calculated as: (mean µg of analyte in feces/ mean µg of analyte administered) × 100

**2.6.5.5. PHARMACOKINETICS: ORGAN DISTRIBUTION**

**Test Article: modRNA encoding luciferase in LNP  
Report Number: R-20-0072**

Species (Strain):	Mice (BALB/c)
Sex/Number of Animals:	Female/3 per group
Feeding Condition:	Fed ad libitum
Vehicle/Formulation:	Phosphate-buffered saline
Method of Administration:	Intramuscular injection
Dose (mg/kg):	1 µg/hind leg in gastrocnemius muscle (2 µg total)
Number of Doses:	1
Detection:	Bioluminescence measurement
Sampling Time (hour):	6, 24, 48, 72 hours; 6 and 9 days post-injection

Time point	Total Mean Bioluminescence signal (photons/second)		Mean Bioluminescence signal in the liver (photons/second)
	Buffer control	modRNALuciferase in LNP	modRNALuciferase in LNP
6 hours	1.28×10 <sup>5</sup>	1.26×10 <sup>9</sup>	4.94×10 <sup>7</sup>
24 hours	2.28×10 <sup>5</sup>	7.31×10 <sup>8</sup>	2.4×10 <sup>6</sup>
48 hours	1.40×10 <sup>5</sup>	2.10×10 <sup>8</sup>	Below detection <sup>a</sup>
72 hours	1.32×10 <sup>5</sup>	7.87×10 <sup>7</sup>	Below detection <sup>a</sup>
6 days	1.62×10 <sup>5</sup>	2.02×10 <sup>6</sup>	Below detection <sup>a</sup>
9 days	7.66×10 <sup>4</sup>	5.09×10 <sup>5</sup>	Below detection <sup>a</sup>

LNP = Lipid nanoparticle; modRNA = Nucleoside modified messenger RNA.

a. At or below the background level of the buffer control.

090177e1950bbf6fApproved On: 29-Sep-2020 20:17 (GMT)

**2.6.5.9. PHARMACOKINETICS: METABOLISM IN VIVO, RAT****Test Article: modRNA encoding luciferase in LNP  
Report Number: PF-07302048\_05Aug20\_043725**

Species (Strain): Rat (Wistar Han)  
 Sex/ Number of animals: Male/ 36 animals total for plasma and urine, 3 animals for urine and feces  
 Method of Administration: Intravenous  
 Dose (mg/kg): 1  
 Test System: Plasma, Urine, Feces, Liver  
 Analysis Method: Ultrahigh performance liquid chromatography/ mass spectrometry

Biotransformation	m/z	Metabolites of ALC-0315 Detected			
		Plasma	Urine	Feces	Liver
<i>N</i> -dealkylation, oxidation	102.0561 <sup>a</sup>	ND	ND	ND	ND
<i>N</i> -Dealkylation, oxidation	104.0706 <sup>b</sup>	ND	ND	ND	ND
<i>N</i> -dealkylation, oxidation	130.0874 <sup>a</sup>	ND	ND	ND	ND
<i>N</i> -Dealkylation, oxidation	132.1019 <sup>b</sup>	ND	ND	ND	ND
<i>N</i> -dealkylation, hydrolysis, oxidation	145.0506 <sup>a</sup>	ND	ND	ND	ND
Hydrolysis (acid)	255.2330 <sup>a</sup>	+	ND	ND	ND
Hydrolysis, hydroxylation	271.2279 <sup>a</sup>	ND	ND	ND	ND
Bis-hydrolysis (amine)	290.2690 <sup>b</sup>	+	+	+	+
Hydrolysis, glucuronidation	431.2650 <sup>a</sup>	ND	ND	ND	ND
Bis-hydrolysis (amine), glucuronidation	464.2865 <sup>a</sup>	ND	ND	ND	ND
Bis-hydrolysis (amine), glucuronidation	466.3011 <sup>b</sup>	ND	+	ND	ND
Hydrolysis (amine)	528.4986 <sup>b</sup>	+	ND	ND	+
Hydrolysis (amine), Glucuronidation	704.5307 <sup>b</sup>	ND	ND	ND	ND
Oxidation to acid	778.6930 <sup>a</sup>	ND	ND	ND	ND
Oxidation to acid	780.7076 <sup>b</sup>	ND	ND	ND	ND
Hydroxylation	782.7232 <sup>b</sup>	ND	ND	ND	ND
Sulfation	844.6706 <sup>a</sup>	ND	ND	ND	ND
Sulfation	846.6851 <sup>b</sup>	ND	ND	ND	ND
Glucuronidation	940.7458 <sup>a</sup>	ND	ND	ND	ND
Glucuronidation	942.7604 <sup>b</sup>	ND	ND	ND	ND

Note: Both theoretical and observed metabolites are included.

m/z = mass to charge ratio; ND = Not detected; + = minor metabolite as assessed by ultraviolet detection.

a. Negative ion mode.

b. Positive ion mode.

## 2.6.5.10A. PHARMACOKINETICS: METABOLISM IN VITRO

Test Article: ALC-0315  
 Report Numbers: 01049-20008  
 01049-20009  
 01049-20010

Type of Study:	Liver Microsomes + NADPH					Stability of ALC-0315 In Vitro S9 Fraction + NADPH, UDPGA, and alamethicin				Hepatocytes				
ALC-0315 Concentration:	1 µM					1 µM				1 µM				
Duration of Incubation (min):	120 min					120 min				240 min				
Analysis Method:	Ultra-high performance liquid chromatography-tandem mass spectrometry													
Incubation time (min)	Percent ALC-0315 remaining													
	Liver Microsomes					Liver S9 Fraction				Hepatocytes				
	Mouse (CD- 1/ICR)	Rat (SD)	Rat (WH)	Monkey (Cyno)	Human	Mouse (CD- 1/ICR)	Rat (SD)	Monkey (Cyno)	Human	Mouse (CD- 1/ICR)	Rat (SD)	Rat (WH)	Monkey (Cyno)	Human
0	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
15	98.77	94.39	96.34	97.96	100.24	97.69	98.85	99.57	95.99	--	--	--	--	--
30	97.78	96.26	97.32	96.18	99.76	97.22	99.62	96.96	97.32	101.15	97.75	102.70	96.36	100.72
60	100.49	99.73	98.54	100.00	101.45	98.61	99.62	99.13	94.98	100.77	98.50	102.32	97.82	101.44
90	97.78	98.66	94.15	97.96	100.48	98.15	98.85	98.70	98.33	101.92	99.25	103.09	100.0	100.36
120	96.54	95.99	93.66	97.71	98.31	96.76	98.46	99.57	99.33	98.85	97.38	99.61	96.36	100.72
180	--	--	--	--	--	--	--	--	--	101.15	98.88	103.47	95.64	98.92
240	--	--	--	--	--	--	--	--	--	99.62	101.12	100.00	93.82	99.64
t <sub>1/2</sub> (min)	>120	>120	>120	>120	>120	>120	>120	>120	>120	>240	>240	>240	>240	>240

-- = Data not available; ALC-0315 = (4-hydroxybutyl)azanediylbis(hexane-6,1-diyl)bis(2-hexyldecanoate), a proprietary aminolipid included as an excipient in the lipid nanoparticle formulation used in BNT162b2; Cyno = Cynomolgus; NADPH = Reduced form of nicotinamide adenine dinucleotide phosphate; NC = not calculated; SD = Sprague Dawley; t<sub>1/2</sub> = half-life; WH = Wistar-Han; UDPGA= uridine-diphosphate-glucuronic acid trisodium salt.

**2.6.5.10B. PHARMACOKINETICS: METABOLISM IN VITRO  
CONTINUED**

Test Article: ALC-0159  
Report Numbers: **01049-20020**  
**01049-20021**  
**01049-20022**

Type of Study:	Liver Microsomes + NADPH					Stability of ALC-0159 In Vitro S9 Fraction + NADPH, UDPGA, and alamethicin				Hepatocytes				
Study System:														
ALC-0159 Concentration:	1 µM					1 µM				1 µM				
Duration of Incubation (min):	120 min					120 min				240 min				
Analysis Method:	Ultra-high performance liquid chromatography-tandem mass spectrometry													
Incubation time (min)	Percent ALC-0159 remaining													
	Liver Microsomes					Liver S9 Fraction				Hepatocytes				
	Mouse (CD- 1/ICR)	Rat (SD)	Rat (WH)	Monkey (Cyno)	Human	Mouse (CD-1/ICR)	Rat (SD)	Monkey (Cyno)	Human	Mouse (CD- 1/ICR)	Rat (SD)	Rat (WH)	Monkey (Cyno)	Human
0	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
15	82.27	101.24	112.11	100.83	99.59	98.93	84.38	91.30	106.73	--	--	--	--	--
30	86.40	93.78	102.69	85.12	92.28	91.10	90.87	97.96	107.60	100.85	93.37	113.04	90.23	106.34
60	85.54	98.34	105.38	86.36	95.53	102.85	97.97	105.56	104.97	94.92	91.81	105.07	92.93	101.58
90	85.41	95.44	100.90	94.63	97.97	90.75	93.51	108.33	109.36	94.28	90.25	112.80	94.59	92.67
120	95.87	97.10	108.97	93.39	93.09	106.76	92.70	105.74	119.59	87.08	89.47	104.11	97.51	96.04
180	--	--	--	--	--	--	--	--	--	94.92	93.96	102.90	89.81	93.66
240	--	--	--	--	--	--	--	--	--	102.75	94.93	98.79	92.93	102.57
t <sub>½</sub> (min)	NC	>120	NC	>120	>120	>120	>120	>120	>120	>240	>240	>240	>240	>240

-- = Data not available; ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, a proprietary polyethylene glycol-lipid included as an excipient in the lipid nanoparticle formulation used in BNT162b2; Cyno = Cynomolgus; NADPH = Reduced form of nicotinamide adenine dinucleotide phosphate; NC = not calculated; SD = Sprague Dawley; WH = Wistar-Han; UDPGA= uridine-diphosphate-glucuronic acid trisodium salt.

090177e1950bbf6f1ApprovedApproved On: 29-Sep-2020 20:17 (GMT)



### 2.6.5.10C. PHARMACOKINETICS: METABOLISM IN VITRO CONTINUED

Test Article: ALC-0315  
Report Number: PF-07302048\_05Aug20\_043725

Type of study		Metabolism of ALC-0315 In Vitro											
Study system		Blood				Hepatocytes				Liver S9 Fraction			
ALC-0315 concentration		10 µM				10 µM				10 µM			
Duration of incubation		24 h				4 h				24 h			
Analysis Method:		Ultrahigh performance liquid chromatography/ mass spectrometry											
Biotransformation	m/z	Blood				Hepatocytes				Liver S9 Fraction			
		Mouse	Rat	Monkey	Human	Mouse	Rat	Monkey	Human	Mouse	Rat	Monkey	Human
<i>N</i> -dealkylation, oxidation	102.0561 <sup>a</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
<i>N</i> -Dealkylation, oxidation	104.0706 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
<i>N</i> -dealkylation, oxidation	130.0874 <sup>a</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
<i>N</i> -Dealkylation, oxidation	132.1019 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
<i>N</i> -dealkylation, hydrolysis, oxidation	145.0506 <sup>a</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Hydrolysis (acid)	255.2330 <sup>a</sup>	+	+	ND	ND	+	+	+	+	+	+	ND	+
Hydrolysis, hydroxylation	271.2279 <sup>a</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Bis-hydrolysis (amine)	290.2690 <sup>b</sup>	+	+	ND	ND	ND	ND	ND	ND	ND	ND	+	ND
Hydrolysis, glucuronidation	431.2650 <sup>a</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Bis-hydrolysis (amine), glucuronidation	464.2865 <sup>a</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Bis-hydrolysis (amine), glucuronidation	466.3011 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Hydrolysis (amine)	528.4986 <sup>b</sup>	ND	+	ND	ND	ND	ND	ND	ND	ND	ND	+	ND
Hydrolysis (amine), glucuronidation	704.5307 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Oxidation to acid	778.6930 <sup>a</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Oxidation to acid	780.7076 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Hydroxylation	782.7232 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Sulfation	844.6706 <sup>a</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Sulfation	846.6851 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Glucuronidation	940.7458 <sup>a</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Glucuronidation	942.7604 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND

Note: Both theoretical and observed metabolites are included.

m/z = mass to charge ratio; ND = Not detected; + = metabolite present.

a. Negative ion mode.

b. Positive ion mode.

### 2.6.5.10D. PHARMACOKINETICS: METABOLISM IN VITRO CONTINUED

Test Article: ALC-0159  
Report Number: PF-07302048\_05Aug20\_043725

Type of study		Metabolism of ALC-0159 In Vitro											
Study system		Blood				Hepatocytes				Liver S9 Fraction			
ALC-0159 concentration		10 µM				10 µM				10 µM			
Duration of incubation		24 h				4 h				24 h			
Analysis Method:		Ultrahigh performance liquid chromatography/ mass spectrometry											
Biotransformation	m/z	Blood				Hepatocytes				Liver S9 Fraction			
		Mouse	Rat	Monkey	Human	Mouse	Rat	Monkey	Human	Mouse	Rat	Monkey	Human
<i>O</i> -Demethylation, <i>O</i> -dealkylation	107.0703 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
<i>O</i> -Demethylation, <i>O</i> -dealkylation	151.0965 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
<i>O</i> -Demethylation, <i>O</i> -dealkylation	195.1227 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Hydrolysis, <i>N</i> -Dealkylation	214.2529 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
<i>N</i> -Dealkylation, oxidation	227.2017 <sup>a</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Hydrolysis (amine)	410.4720 <sup>b</sup>	+	+	ND	ND	+	+	+	+	+	+	+	+
<i>N,N</i> -Didealkylation	531.5849 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
<i>N</i> -Dealkylation	580.6396 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
<i>O</i> -Demethylation, oxidation	629.6853 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Hydroxylation	633.6931 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
$\omega$ -Hydroxylation, Oxidation	637.1880 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Hydrolysis (acid)	708.7721 <sup>b</sup>	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND

Note: Both theoretical and observed metabolites are included.

m/z = mass to charge ratio; ND = Not detected; + = metabolite present.

a. Negative ion mode.

b. Positive ion mode.